Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D Confidence in Abecma's competitive profile further reinforced by real world evidence R/R MM Efficacy Outcomes¹ Best ORR 84% 73% R/R MM Safety Outcomes¹ Best Response ≥ CR Any CRS/Grade ≥3 Any NT/Grade ≥3 42% 33% 84% 82% iber/mezi ide-cel RWE Predictable safety profile well understood Real world data confirms the efficacy profile in a real world population Strong manufacturing reliability confirmed: 94% success rate Data supports CAR T before other BCMA-targeted therapies in the real world² 18% 18% 5% 3% 3% 6% ide-cel KarMMa ide-cel RWE ide-cel KarMMa ide-cel RWE ide-cel KarMMa ide-cel RWE ide-cel KarMMa ide-cel KarMMa (Phase 2 cohort), n=128 ide-cel RWE, n=159 Ill Bristol Myers Squibb™ 1. Hansen DK, et al. J Clin Oncol. 2023;41:2087-97. 2. Ferreri CJ, et al. Blood Cancer J. 2023;13:117. Including antibody drug conjugate, bispecific antibody, or BCMA CART on clinical trial Not for Product Promotional Use 82

View entire presentation